HC Wainwright Gives Atossa Therapeutics a 'Buy' Rating

Analysts at HC Wainwright have reaffirmed their "buy" rating for Atossa Therapeutics (NASDAQ:ATOS) in a research note published on Thursday. They have set a price target of $6.00 for the stock, which suggests a remarkable potential upside of 337.96% from its current trading price.

In addition to HC Wainwright's assessment, Atossa has caught the attention of other financial analysts. Ascendiant Capital Markets raised their price target for Atossa Therapeutics from $6.25 to $6.50, maintaining a "buy" rating in their report dated September 11. Meanwhile, StockNews.com shifted its stance on Atossa's shares, upgrading them from a "sell" to a "hold" rating on October 25.

Recent Stock Movement

On Thursday, Atossa Therapeutics saw its stock price decrease by $0.04, closing at $1.37. A total of 230,103 shares changed hands during trading, which is significantly lower than the average trading volume of 1,086,837 shares. The company's market capitalization stands at $172.29 million, with a negative price-to-earnings (PE) ratio of -5.75 and a beta of 1.20. Over the last 50 days, the stock has had a moving average price of $1.43, while the 200-day moving average is $1.38. In the past year, Atossa's stock has seen lows of $0.62 and highs of $2.31.

Atossa Therapeutics disclosed its latest quarterly earnings on August 12, where it reported an earnings per share (EPS) of ($0.05), slightly surpassing analysts' predictions of ($0.06). Looking ahead, analysts forecast that the company will report an EPS of -0.22 for the ongoing year.

Institutional Investor Activity

Recent activity among institutional investors shows a mix of increased and new stakes in Atossa Therapeutics. Vanguard Group Inc. has raised its stake in the company by 1.4% during the first quarter, now owning 5,753,993 shares valued at approximately $10.36 million. Other notable actions include Virtu Financial LLC establishing a new position worth $151,000 and Cetera Advisors LLC acquiring shares valued at $72,000 during the same period. Furthermore, Bank of New York Mellon Corp significantly increased its holdings by 3,160.5% in the second quarter, ending up with 411,667 shares worth about $490,000. Collectively, institutional investors control around 12.74% of Atossa's stock.

About Atossa Therapeutics

Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies addressing significant medical needs in oncology, particularly for women's breast cancer and related conditions in the United States. Its leading candidate is oral (Z)-endoxifen, which is currently in Phase II clinical trials aimed at treating and preventing breast cancer.

Conclusion

With reaffirmed buy ratings and growing institutional interest, Atossa Therapeutics is positioned for potential upside as it continues its clinical development in oncology. Investors keep a close watch on the company's progress, the stock's performance, and what its planned advancements might mean for future earnings.

Atossa, Investors, Stock